Clinical effects of isoflavones. Further research is required to characterize the pharmacokinetics of isoflavones. The optimal dose of isoflavone required to have clinical effects remains to be established for most of the hormone-dependent conditions under investigation. Results from our previous human studies in healthy premenopausal women indicate that 50 mg/d of aglycones is sufficient to have significant endocrine effects (Cassidy et al. 1994[] ), whereas half this dose appears biologically inactive (Cassidy et al. 1995[] ). Dose and duration of intake will likely be the major factors that influence the clinical and biological outcome of a phytoestrogen-rich diet. Rigorous compliance to dietary regimens of soy foods containing isoflavones remains a major challenge in clinical and nutritional studies. Improvements in food technology are required, and genetic modifications of the soybean and other plants to enhance isoflavone production seem inevitable.   Dietary interventions and more Discussion of soy and more Not many studies available Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.